A
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals: Developing Treatments for Dry-AMD & Stargardt disease
About Alkeus Pharmaceuticals
Alkeus Pharmaceuticals is a biotech startup that operates in the healthcare sector, specifically focusing on the development of treatments for genetic eye diseases. The company's primary product is ALK-001, a breakthrough therapy designed to treat Stargardt disease, a common genetic cause of blindness in children and young adults. Currently, there is no treatment for this disease, which affects over 30,000 people in the United States alone.
Stargardt disease is caused by defects in the ABCA4 gene, which results in the accumulation of toxic by-products in the eye, leading to progressive vision loss. Alkeus's ALK-001 is a modified version of vitamin A, designed to perform all the functions of vitamin A needed for sight, but without the tendency to form these toxic by-products.
The company's business model is based on the research, development, and eventual sale of this breakthrough therapy. They make money by developing and patenting their unique treatments, and then selling them to healthcare providers and patients. Their primary market is individuals suffering from Stargardt disease, but their research could potentially be applicable to other genetic eye diseases as well.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Boston, United States
- Employees
- 55
- Open positions
- None listed
- Dealroom signal
- 27.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2023 | $150M | $600M | Wellington Management · TCGX · Sofinnova Investments · Bain Capital Life Sciences | ↗ |
| GRANTOther financing | Oct 2011 | $100K | — | MassChallenge | — |
Growth signals
Latest recorded traffic for Alkeus Pharmaceuticals is 360 monthly website visits, down 60.4% over the last three months. Alkeus Pharmaceuticals's team declined 21.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
MassChallenge
Series A4 investors entered at this stage
Wellington Management
TCGX
Sofinnova Investments
Bain Capital Life Sciences
Other known investors1 additional known investor
Columbia University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alkeus Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alkeus Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.